Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations (CROSBI ID 260881)

Prilog u časopisu | pregledni rad (stručni)

Prpić, Marin ; Franceschi, Maja ; Romić, Matija ; Jukić, Tomislav ; Kusić, Zvonko Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations // Acta clinica Croatica, 57 (2018), 3; 518-527. doi: 10.20471/acc.2018.57.03.16

Podaci o odgovornosti

Prpić, Marin ; Franceschi, Maja ; Romić, Matija ; Jukić, Tomislav ; Kusić, Zvonko

engleski

Thyroglobulin as a Tumor Marker in Differentiated Thyroid Cancer – Clinical Considerations

Initial treatment of the majority of patients with differentiated thyroid cancer (DTC) includes total thyroidectomy. Postoperative ablation therapy with radioactive iodine (I- 131) is indicated in all high-risk patients, however, there is disagreement regarding its use in low- and intermediate-risk patients. Over the last few decades, thyroglobulin (Tg) has been established as the primary biochemical tumor marker for patients with DTC. Thyroglobulin can be measured during thyroid hormone therapy or after thyroid-stimulating hormone (TSH) stimulation, through thyroid hormone withdrawal or the use of human recombinant TSH. In many studies, the cut-off value for adequate Tg stimulation is a TSH value >= 30 mIU/L. However, there is an emerging body of evidence suggesting that this long-established standard should be re- evaluated, bringing this threshold into question. Recently, a risk stratification system of response to initial therapy (with four categories) has been introduced and Tg measurement is one of the main components. The relationship between the Tg/TSH ratio and the outcome of radioiodine ablation has also been studied, as well as clinical significance of serum thyroglobulin doubling-time. The postoperative serum Tg value is an important prognostic factor that is used to guide clinical management, and it is the most valuable tool in long term follow-up of patients with DTC.

Thyroglobulin ; Thyroid neoplasms ; Thyroidectomy ; Iodine radioisotopes ; Biomarkers, tumor ; Thyroid hormones ; Croatia

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

57 (3)

2018.

518-527

objavljeno

0353-9466

1333-9451

10.20471/acc.2018.57.03.16

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti

Poveznice
Indeksiranost